These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 17043955

  • 1. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].
    Zhan WH, Wang PZ, Shao YF, Wu XT, Gu J, Li R, Wan DS, Ding KF, Shi YQ, Yu JR, Lu HS, Zou XM, Bi JW, Sun YH, Lu YF, Chen DD, Zhang XH.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep; 9(5):383-7. PubMed ID: 17043955
    [Abstract] [Full Text] [Related]

  • 2. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H, Zhang Y, Wang M, Shen DP, Sheng ZY, Ni XZ, Wu ZY, Liu Q, Shen YY, Song YY.
    Chin Med J (Engl); 2010 Jan 20; 123(2):131-6. PubMed ID: 20137358
    [Abstract] [Full Text] [Related]

  • 3. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
    Higashi D, Watanabe Y, Hirano K, Shimomura T, Egawa Y, Tomiyasu T, Ishibashi Y, Futami K, Maekawa T, Ota A, Oshige K, Iwashita A.
    Anticancer Res; 2009 Nov 20; 29(11):4893-6. PubMed ID: 20032453
    [Abstract] [Full Text] [Related]

  • 4. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease.
    An JY, Choi MG, Noh JH, Sohn TS, Kang WK, Park CK, Kim S.
    Eur J Surg Oncol; 2007 Oct 20; 33(8):1030-5. PubMed ID: 17428635
    [Abstract] [Full Text] [Related]

  • 5. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygut J, Nyckowski P, Krawczyk M, Ruka W.
    Med Sci Monit; 2007 Nov 20; 13(11):CR515-522. PubMed ID: 17968300
    [Abstract] [Full Text] [Related]

  • 6. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.
    Anticancer Drugs; 2008 Jul 20; 19(6):607-12. PubMed ID: 18525320
    [Abstract] [Full Text] [Related]

  • 7. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK, Kang BW, Im SA, Lee JL, Park SR, Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH.
    Cancer Chemother Pharmacol; 2013 Jan 20; 71(1):43-51. PubMed ID: 23053257
    [Abstract] [Full Text] [Related]

  • 8. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW.
    Ann Surg Oncol; 2007 Jan 20; 14(1):14-24. PubMed ID: 17072676
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).
    Nilsson B, Sjölund K, Kindblom LG, Meis-Kindblom JM, Bümming P, Nilsson O, Andersson J, Ahlman H.
    Br J Cancer; 2007 Jun 04; 96(11):1656-8. PubMed ID: 17533389
    [Abstract] [Full Text] [Related]

  • 10. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L, Jin ML.
    Zhonghua Zhong Liu Za Zhi; 2004 Nov 04; 26(11):697-9. PubMed ID: 15777512
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
    Jiang WZ, Guan GX, Lu HS, Yang YH, Kang DY, Huang HG.
    J Surg Oncol; 2011 Dec 04; 104(7):760-4. PubMed ID: 21713778
    [Abstract] [Full Text] [Related]

  • 12. Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients.
    Saied GM, Kensarah AM.
    Int J Surg; 2010 Dec 04; 8(2):105-8. PubMed ID: 19944196
    [Abstract] [Full Text] [Related]

  • 13. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC.
    J Clin Oncol; 2008 Feb 01; 26(4):626-32. PubMed ID: 18235122
    [Abstract] [Full Text] [Related]

  • 14. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
    Benjamin RS, Blanke CD, Blay JY, Bonvalot S, Eisenberg B.
    Oncologist; 2006 Jan 01; 11(1):9-20. PubMed ID: 16401709
    [Abstract] [Full Text] [Related]

  • 15. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
    Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D.
    J Clin Oncol; 2007 Mar 20; 25(9):1107-13. PubMed ID: 17369574
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
    Zhu J, Wang Y, Hou M, Li HY, Zhang J.
    Oncology; 2007 Mar 20; 73(5-6):324-7. PubMed ID: 18497504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.